ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02 2019 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday,
January 9, 2019 at 1:30 p.m. PST. The conference will be held at
the Westin St. Francis in San Francisco, CA.
A live audio webcast of the presentation can be accessed through
the Investors section of the Company's website at
www.ChemoCentryx.com. A replay of the webcast will be available on
the Company's website for two weeks following the live
presentation.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally-administered
therapies. ChemoCentryx is currently focusing on its late stage
drug candidates for patients with rare diseases, avacopan (CCX168)
and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(ANCA-associated Vasculitis). In clinical studies to date, avacopan
was shown to be safe, well tolerated and provided effective control
of the disease while allowing elimination of high-dose steroids,
part of the current standard of care. ChemoCentryx is also
developing avacopan for the treatment of patients with C3
glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S.
Food and Drug Administration has granted avacopan orphan-drug
designation for ANCA-associated Vasculitis, C3G and atypical
hemolytic uremic syndrome (aHUS). The European Commission has
granted orphan medicinal product designation for avacopan for the
treatment of two forms of ANCA-associated Vasculitis: microscopic
polyangiitis and granulomatosis with polyangiitis (formerly known
as Wegener's granulomatosis), as well as for C3G. Avacopan was also
granted access to the European Medicines Agency's (EMA) PRIority
MEdicines (PRIME) initiative, which supports accelerated assessment
of investigational therapies addressing unmet medical need.
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease. The U.S.
Food and Drug Administration has granted CCX140 orphan-drug
designation for the treatment of FSGS.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Source: ChemoCentryx, Inc.CCXI-G
Contacts:
Susan M.
Kanaya
Executive Vice President,
Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:William Slattery, Jr., Burns
McClellan212.213.0006
bslattery@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024